Relapsed Leukemia Research Paper

After completing fellowship training in 2013, I have continued to commit 75% effort towards conducting research. Based on our preliminary data, we propose to study the role of CK2-Ikaros in Acute Myeloid Leukemia (AML) in children and for the first time test the therapeutic efficacy of a CK2 inhibitor in treatment of AML using Primary Patient Derived Xenograft (PDX) mouse models. Support from the Hyundai' Hope on Wheels' Young Investigator Award will ensure continued protected time to conduct research and produce promising results and publications. If successful, these results will open doors for further clinical testing of CK2 inhibitors as novel therapy for treatment of AML in children. This will be an important milestone for my transition towards becoming an independent investigator. I am strongly committed to a career as a physician-scientist with a focus on translational research in childhood cancer. My previous training, productivity, mentorship and the outstanding research environment at Pennsylvania State University Children’s Hospital, provide assurance that I will successfully complete the proposed

Leukemia is a type of cancer that sadly causes around 25,000 deaths in the U.S. each year. The area that it affects is the blood and the bone marrow and like most or all of the types of cancer in the world if not taken control of early it will most likely kill you.

The number of older individuals undergoing HSCT for malignant disease has risen considerably over the years. Between 2007- 2013, 22% of allogeneic transplants and 44% of autologous transplants were in patients older than 60 years of age1. The rise of HSCT in this age group can be attributed to the use of reduced intensity conditioning (RIC) regimen and advances in post-HSCT supportive care2,3. HSCT is a potential curative treatment for a number of malignant hematologic diseases such as myelodysplastic syndrome (MDS), leukemia, lymphoma and myeloma which tend to more commonly affect the elderly population. For instance, according to the SEER database, the median age of diagnosis of acute myeloid leukemia (AML) and MDS are 67 and 70 years respectively. Despite these findings, the number of patients over the age of 65 undergoing allogeneic HSCT remains low4. An evaluation of the NIH clinical trial registry revealed that 90% of HSCT clinical trials excluded older individuals (>75 years), 75% based on chronologic age, 39% based on performance status in the elderly and 39% based on organ function in the elderly5. Inadequate accrual remains a problem even for trials that allow older patients, mostly due to physician reluctance, comorbidities and performance status6.

Secondary MDS occurs because of damage to the DNA from chemotherapy or radiation therapy previously given to treat another medical condition, and is often associated with more complex chromosomal abnormalities. These classifications help doctors plan treatment and predict a patient's prognosis. About 13,000 people in the United States are diagnosed with MDS each year and approximately one-third of the patients with MDS develop AML. MDS is often rare in people younger than 40, so most people that are diagnosed with MDS are older than 60. Death from MDS is often caused by bleeding and infection from low blood cell counts or after the disease becomes acute myeloid leukemia (AML). Doctors use many tests to diagnose MDS and some of the tests may also determine which treatments may be the most effective. In addition to a physical examination, there are several tests to take to diagnose MDS, including: blood tests, peripheral blood smears, bone marrow aspiration and biopsy, molecular testing, cytogenic analysis and

Chronic Lymphocytic Leukemia (CLL) is a cancer that primarily found in the blood and bone marrow. Because this cancer progresses slower than other types of leukemia it is referred to as chronic. This type of cancer affect the white blood cell that is known as the lymphocyte. The white blood cells that are affected help to protect the body by fighting off infection. Lymphocytes are made in the center of the bone also known as bone marrow. The lymphocytes that are produced in these patients are produced at abnormal rates and do not function correctly. Older adults are the most prone then others to getting this type of leukemia. This cancer is slow acting and it could take years before symptoms appear. People who receive treatment may live longer than those who choose not to treat it. Other types of people who are more likely to get this type are those with a family history, a Caucasian male, or if you have relatives that are either Eastern European or Russian Jew.

Multiple myeloma (MM) is a cancer of plasma cells and every year 1500 Australians are diagnosed with the disease. Treatment options consist of chemotherapy alone or in combination with corticosteroids such as dexamethasone or prednisone and stem cell transplants being a last resort option in otherwise healthy individuals. In relapsed and/or refractory cases treatment includes specific antineoplastic drugs such as bortezomib, a proteasome inhibitor or immunomodulatory drugs such as thalidomide [3].

Leukemia is the leading cancer in children. When a cancer patient undergoes Leukemia treatment, they are told the risks and dangers. A cancer patient understands the risks and what they must face in order to beat the cancer. The type of treatment and its dosage has the greatest impact on a patient’s health. I went through this treatment when I battled with cancer. I knew the risks and problems

There are four main types of blood cancers: acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL). AML and ALL can become fatal within in a few weeks or month if not properly treated. CML and CLL has a slower progression rate than there chronic counterparts. Patients with AML or ALL tend to have noticeable symptoms whereas patients with CML or CLL tend to be asymptomatic (Hallek, 2015). Even though chronic leukemia progresses slowly, acute leukemia is easier to treat. In AML patients’ myeloid blast are arrested in development and are unable to fight infections properly because they are unable to mature (Döhner et al, 2015). Myeloid blast in CML can mature

Leukemia is a type of cancer in the bone marrow. The bone marrow produces three types of blood cells that keep your body functioning. When you have Leukemia the blood cells in your bone marrow stop working. Approximately 58,000 people die of leukemia every year. There are many types of Leukemia, but thankfully there are also many types of treatments.

Under the supervision of Dr. Alan Lichtin. I wrote the manuscript for a blood work project that looks at unusual MRI appearance of leukemic relapse. I also was responsible for getting the images from diagnostic radiology and pathology labs. The blood work was submitted to Blood Journal on February

Jack woke up one morning not feeling well. He felt very weak and could not get out of bed. His mother decided to take him to the doctors. The doctors took many tests to figure out what was making him feel that way. After about an hour or two the doctors got the results back from a blood test. Results that would change Jack’s childhood for the worse. Jack has been diagnosed with Leukemia, a blood cancer. Of course, Jack was not sure what that meant but, his parents became worried beyond belief with the long road ahead of them. Scientists and researchers were all involved in the discovery of Leukemia cancer, which increased knowledge of this cancer, decreased deaths and discovered treatments, and started charity groups to fund research.

Leukemia is a cancer of the blood cells where abnormally high counts of white blood cells are produced in the bone marrow. These are the primary cells in the body that fight infection but when they are abnormal as in this case, they cannot be an effective defense mechanism. In their normal routines of fighting infection, controlling bleeding, and transport of oxygen, the normal functions of the body begin to break down often leading to fatality.

The treatment of secondary AML and post myelodysplastic not differ from the rest of AML, although the probability of achieving a complete remission maintained is much lower because of its greater resistance to chemotherapies. In these cases, if feasible, it is customary

Leukeumia is a type of cancer affecting the bone marrow. Bone marrow is where platelets, red blood cells and white blood cells (Leukocytes) are made. (Medical Journal Dictionary)Leukemia is caused by the rapid production (Proliferation) of Leukocytes, and causes a build-up that inhibits red blood cells, and platelets from functioning and stops other Leukocytes from fighting infection. Because of the abnormally rapid production these cells are unable to mature or develop properly and are unable to carry out their functions. (Almeida & Barry, 2010) There are four main types of Leukemia, each classified by how rapid the disease develops and which type of white blood cell is affected; Acute which is a rapid

Today, the topic of stem cells is a highly discussed, controversial one. It seems as though there is always something being said about new findings in stem cell research and what will be done with the newly-found information. One of the most conversed aspects of stem cell research is how stem cells can be used to treat potentially life-threatening conditions. Leukemia is one of the conditions being researched along with how stem cell therapy could help benefit the patients with it. In order to fully understand what is going on in the world of stem cell and leukemia research, one must first know what stem cells are and what leukemia is.